The licensing agreement for Plendil will close at signing and revenue from the agreement will be reported as Externalisation Revenue in AstraZeneca’s financial statements. Plendil, while a mature brand in AstraZeneca’s portfolio, represents a significant commercial opportunity in China, supported by our long track record in the market, our nationwide coverage and expertise.” Lam Kong, Chairman and Chief Executive Officer at China Medical System Holdings Ltd said: “We are pleased to be entering into this agreement with AstraZeneca. The agreement ensures widespread patient access to an established medicine and continued long-term revenues, while focusing our resources on commercialising innovative new medicines from our pipeline across our main therapy areas.” Mark Mallon, Executive Vice President, International at AstraZeneca, said: “This commercial collaboration supports our strategy of working with a local partner to maximise the value from our medicines in China, our second largest market globally. The transaction does not include the transfer of any AstraZeneca employees or facilities.
AstraZeneca will retain the global rights to Plendil outside China. AstraZeneca will maintain a significant, long term interest in the future value derived from Plendil sales in China and will manufacture and supply the medicine to CMS.
#Astra cms license#
Under the terms of the agreement, CMS will pay AstraZeneca $310 million for the license to sell Plendil in China. Plendil was first approved in China in 1995 for the treatment of hypertension or high blood pressure and in 2015 achieved Product Sales of $189 million.
Partnerships, alliances and recognitionĪgreement for Plendil in China reinforces AstraZeneca’s focus on innovative medicinesĪstraZeneca today announced it has entered into a licensing agreement with China Medical System Holdings Ltd (CMS) for the commercialisation rights in China to its calcium channel blocker, Plendil (felodipine). "Aveco was able to easily adapt their system under a tight delivery schedule to help us meet the demanding expectations of a very experienced broadcaster," said Francisco De Marco, General Manager at FDM Broadcast, supplier and the turn-key system integrator for the project.Īveco and FDM Broadcast worked together with Grass Valley and SAV to get the system successfully on-air. "This customized service is something we offer all customers, small or large." "While Sersat was a standard project for us, we still tailored the system to their specific workflow needs with many features including a custom playlist import and as-run log export," said Roger Crooks, VP Sales and Marketing at Aveco. It also manages the disk space of all three K2 media servers by purging old content based on Sersat's clip lifecycle policies. The ASTRA CMS content management system manages ingest from six VTRs to a third ingest K2 media server as well as the file transfers to both mirrored playout servers. The Sersat ASTRA MCR system has four playlists with a custom traffic interface controlling mirrored playout from two Grass Valley K2 media servers. "ASTRA's design around a real-time operating system and their reputation for reliability set them apart from other systems we looked at." Javier Bonini, Technology Manager at Sersat. "We have over 15 years of experience with different automation systems and we were impressed with ASTRA's straight to the point GUI and easy operation. Sersat provides playout and satellite uplink services. Sersat, Argentina Switches to Aveco's ASTRA MCR System for Playout and Uplink ServicesĪveco, the worldwide broadcast facility content management and automation solutions specialist, has installed a four channel ASTRA MCR automation and ASTRA CMS content management system at Sersat in Argentina.
0 kommentar(er)
